Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 1,307 trials

Multiple Myeloma: Iberdomide with Isatuximab

We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHematologyOncology

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

COVID-19 Treatment: RECOVERY Trial

We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.

Pneumonia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Urothelial Cancer: Nivolumab with Relatlimab

We are studying a combination of nivolumab and relatlimab as a pre-surgery treatment for muscle-invasive bladder cancer. The goal is to see if this approach is effective and safe compared to nivolumab alone.

Muscle-Invasive Bladder CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

Acute Myeloid Leukemia: Decitabine and Venetoclax with ATRA

We are studying whether adding all-trans retinoic acid to a treatment regimen helps patients with acute myeloid leukemia who cannot receive standard chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesHematologyOncology

Castration-Resistant Prostate Cancer: Darolutamide with Radiation Therapy

We are studying whether adding stereotactic radiation therapy to darolutamide helps patients with castration-resistant prostate cancer and a few metastases live longer without disease progression. We will also evaluate the treatment's safety and impact on quality of life.

Castration-Resistant Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Hip Replacement Surgery: Shorter Blood Thinner Duration

We are studying whether a shorter course of blood-thinning medication after hip replacement surgery is as effective as the standard duration in preventing blood clots. This trial aims to improve recovery and safety for patients.

Hip Osteoarthritis3-6 monthsConfirmation phase (III)Standard MedicinesHematologyOrthopedics and Traumatology

Lung Cancer Treatment: Entrectinib vs. Crizotinib

We are comparing the effectiveness and safety of two medications for patients with advanced non-small cell lung cancer that has a specific genetic change. This study includes individuals with and without brain metastases.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Venetoclax Treatment Study

We are studying whether adding venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia live longer and achieve better treatment results. This trial compares venetoclax to a placebo to assess its impact on patient outcomes.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)Standard MedicinesHematology

Moderate Acne: Oral Isotretinoin vs. Standard Care

We are comparing a new oral medication to standard treatments for moderate acne in patients with skin of color. Our goal is to see if this new approach improves acne severity and quality of life.

Acne6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDermatology

Basal Cell Carcinomas: Patidegib Gel 2%

We are studying a new gel for adults with Gorlin syndrome to see if it helps prevent basal cell carcinomas on the face. The trial will also check how safe and tolerable the gel is for patients.

Gorlin Syndrome1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyHematology

Atrial Fibrillation: Apixaban vs. Warfarin in Dialysis Patients

We are comparing the safety and effectiveness of apixaban and warfarin for patients with atrial fibrillation on peritoneal dialysis. The study focuses on bleeding risks and the prevention of strokes and other serious health events.

Chronic Ambulatory Peritoneal DialysisConfirmation phase (III)No PlaceboStandard MedicinesCardiologyNephrology

Asciminib Roll-over Study for Leukemia Patients

We are examining the long-term safety of asciminib in patients with certain types of leukemia who have completed a previous study. This trial aims to see if continued treatment is beneficial for these patients.

Chronic Myeloid Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Thyroid Eye Disease: VRDN-001 Treatment Study

We are testing the safety and tolerability of a new monoclonal antibody, VRDN-001, in people with thyroid eye disease. This study involves receiving intravenous infusions to see how well the treatment is tolerated.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyOphthalmology

Extracranial Malignant Germ Cell Tumors: Carboplatin vs. Cisplatin

We are comparing the effectiveness and side effects of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumors. This study aims to improve treatment options and patient quality of life.

Malignant Extracranial Germ Cell Tumours>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pneumococcal Vaccine Study for Infants: PCV21

We are investigating a new 21-valent vaccine for healthy infants starting at 2 months old. The study aims to see if it works as well or better than the current vaccine in protecting against pneumonia.

Pneumococcal ImmunizationConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

Multiple Sclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Breast Imaging: Iodine Contrast Study

We are investigating how effective and safe iodine-based contrast agents are in enhancing mammograms and breast MRIs. This study aims to improve imaging quality for women undergoing these tests.

Breast Cancer>2 yearsConfirmation phase (III)Oncology

Infectious Endocarditis: Shorter Antibiotic Treatment Study

We are investigating whether a shorter course of antibiotics is safe and effective for treating left-sided infectious endocarditis caused by specific bacteria. This study also looks at the potential cost benefits of this accelerated treatment.

Infectious Endocarditis≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInfectious Diseases

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology